No headlines found.
Business Wire (Mon, 1-Apr 8:00 AM ET)
Synlogic Reports Fourth Quarter and Full Year 2023 Financial Results
Globe Newswire (Tue, 19-Mar 7:00 AM ET)
Synlogic Adopts Limited Duration Stockholders Rights Plan
Globe Newswire (Tue, 20-Feb 12:15 PM ET)
Synlogic Announces Decision to Discontinue Synpheny-3 Study and Provides Corporate Update
Globe Newswire (Thu, 8-Feb 4:15 PM ET)
Globe Newswire (Fri, 2-Feb 12:00 PM ET)
Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a lead program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. These drug candidates target specific biological pathways, leveraging Escherichia coli Nissle 1917 for consistency and safety. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one segment-discovery and development of Synthetic Biotics-pioneering transformative treatments for serious diseases.
Synlogic trades on the NASDAQ stock market under the symbol SYBX.
As of April 26, 2024, SYBX stock price climbed to $1.87 with 3,845 million shares trading.
SYBX has a beta of 0.50, meaning it tends to be less sensitive to market movements. SYBX has a correlation of 0.00 to the broad based SPY ETF.
SYBX has a market cap of $21.78 million. This is considered a Sub-Micro Cap stock.
Last quarter Synlogic reported $3 million in Revenue and -$1.71 earnings per share. This beat revenue expectation by $39,000 and missed earnings estimates by -$.74.
In the last 3 years, SYBX stock traded as high as $68.10 and as low as $1.55.
The top ETF exchange traded funds that SYBX belongs to (by Net Assets): VTI, VXF.
SYBX has underperformed the market in the last year with a return of -78.3%, while the SPY ETF gained +26.8%. In the last 3 month period, SYBX fell short of the market, returning -41.7%, while SPY returned +4.5%. However, in the most recent 2 weeks SYBX has outperformed the stock market by returning +6.9%, while SPY returned -1.9%.
SYBX support price is $1.78 and resistance is $1.95 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SYBX stock will trade within this expected range on the day.